Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRVNASDAQ:BTMDNASDAQ:FULCNASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.33-6.7%$3.04$1.27▼$10.16$41.55M1.88189,005 shs506,574 shsBTMDbiote$3.38+4.0%$3.64$3.04▼$8.44$184.92M1.17192,273 shs1.17 million shsFULCFulcrum Therapeutics$5.35-6.6%$3.27$2.32▼$10.13$288.79M2.29962,101 shs890,162 shsGNFTGenfit$4.62+2.0%$3.57$2.55▼$6.42$230.98M0.9214,796 shs11,051 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-6.69%-7.99%-12.25%-80.99%-84.99%BTMDbiote+4.00%-4.52%+2.74%-29.88%-44.22%FULCFulcrum Therapeutics-6.63%+46.58%+113.15%+36.83%-30.97%GNFTGenfit+1.99%+13.93%+37.50%+15.79%+30.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics3.3653 of 5 stars3.55.00.00.03.02.50.6BTMDbiote3.8657 of 5 stars3.55.00.00.03.33.31.3FULCFulcrum Therapeutics1.7137 of 5 stars3.12.00.00.03.21.70.0GNFTGenfit1.1361 of 5 stars3.52.00.00.00.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$19.171,346.54% UpsideBTMDbiote 3.00Buy$8.00136.69% UpsideFULCFulcrum Therapeutics 2.11Hold$8.6361.21% UpsideGNFTGenfit 3.00Buy$13.00181.39% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, FULC, BTMD, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.003/26/2025ACRVAcrivon TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025ACRVAcrivon TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.002/26/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.002/7/2025GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.38 per shareN/ABTMDbiote$197.19M0.94$0.35 per share9.60($0.58) per share-5.83FULCFulcrum Therapeutics$80M3.61N/AN/A$3.80 per share1.41GNFTGenfit$67.00M3.45N/AN/A$1.48 per share3.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$60.39M-$2.44N/AN/AN/AN/A-47.95%-43.73%5/13/2025 (Estimated)BTMDbiote$3.32M$0.1813.006.26N/A5.20%-32.41%22.26%5/7/2025 (Estimated)FULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%5/12/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/ALatest ACRV, FULC, BTMD, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57N/AN/AN/AN/AN/A5/12/2025Q1 2025FULCFulcrum Therapeutics-$0.29N/AN/AN/AN/AN/A5/7/2025Q1 2025BTMDbiote$0.06N/AN/AN/A$47.25 millionN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/27/2025Q4 2024ACRVAcrivon Therapeutics-$0.69-$0.60+$0.09-$0.60N/AN/A2/25/2025Q4 2024FULCFulcrum Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A12.7512.75BTMDbioteN/A1.501.16FULCFulcrum TherapeuticsN/A18.4418.44GNFTGenfit0.613.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%BTMDbiote21.68%FULCFulcrum Therapeutics89.83%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%BTMDbiote24.00%FULCFulcrum Therapeutics4.10%GNFTGenfit4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.36 million28.49 millionNot OptionableBTMDbiote19454.71 million46.78 millionNot OptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableACRV, FULC, BTMD, and GNFT HeadlinesRecent News About These CompaniesGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5 at 1:30 AM | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deGENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 24, 2025 | globenewswire.comGenfit (NASDAQ:GNFT) Stock Price Up 2.1% - What's Next?April 16, 2025 | marketbeat.comGENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 20, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for WeekMarch 14, 2025 | msn.comRoyalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEsMarch 10, 2025 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2024February 27, 2025 | globenewswire.comGENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meetingFebruary 21, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday TradingFebruary 18, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for WeekFebruary 14, 2025 | msn.comGENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs HoldersFebruary 14, 2025 | globenewswire.comGENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025February 6, 2025 | globenewswire.comGenfit SA (GNFT) Receives a Rating Update from a Top AnalystFebruary 3, 2025 | markets.businessinsider.comGENFIT Secures €185 Million Royalty Financing Deal to Bolster R&D and Financial StabilityJanuary 30, 2025 | msn.comGENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution PlanJanuary 30, 2025 | globenewswire.comGENFIT Announces 2025 Financial CalendarJanuary 29, 2025 | globenewswire.comGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialJanuary 13, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Edge Higher in Thursday TradingDecember 26, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, FULC, BTMD, and GNFT Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.32 -0.10 (-6.69%) Closing price 05/6/2025 03:59 PM EasternExtended Trading$1.36 +0.04 (+2.64%) As of 06:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.biote NASDAQ:BTMD$3.38 +0.13 (+4.00%) Closing price 05/6/2025 03:59 PM EasternExtended Trading$3.50 +0.13 (+3.70%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Fulcrum Therapeutics NASDAQ:FULC$5.35 -0.38 (-6.63%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$5.97 +0.62 (+11.66%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Genfit NASDAQ:GNFT$4.62 +0.09 (+1.99%) Closing price 05/6/2025 03:58 PM EasternExtended Trading$4.57 -0.05 (-1.19%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Top-Ranked Insider Buys From April by Market Cap Palantir Stock Drops Despite Stellar Earnings: What's Next? Hims & Hers Stock Rises on Fundamentals and Squeeze Potential Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership? D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Microsoft Stock After Xbox Price Hike: Buy or Hold? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
